2019 ACR/ARP Annual Meeting*

MACE and VTE data were presented for all approved and phase III JAK inhibitors.

Stanley B. Cohen, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: December 5, 2019 Expired: No longer available for credit

Here’s how new strategies like ultralow-dose rituximab, a novel small molecule IRAK-4 inhibitor, and vagus nerve stimulation may or may not change clinical practice.

Jonathan Kay, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Released: January 9, 2020 Expired: No longer available for credit